To further characterize the beneficial impact of testosterone replacement therapy (TRT) on the association between mortality and hypogonadism (HG) in men with type 2 diabetes (T2DM), by determining, firstly, if changes in cardiovascular disease (CVD) risk factors after TRT play a role, secondly, whether the reduction in mortality is lost when TRT is discontinued and, finally, the presence of subgroups where benefit may be greater.
Objectives
To further characterize the beneficial impact of testosterone replacement therapy (TRT) on the association between mortality and hypogonadism (HG) in men with type 2 diabetes (T2DM), by determining, firstly, if changes in cardiovascular disease (CVD) risk factors after TRT play a role, secondly, whether the reduction in mortality is lost when TRT is discontinued and, finally, the presence of subgroups where benefit may be greater.
Materials and Methods
We studied 857 men with T2DM, screened for the BLAST randomized controlled trial, over 3.8 years of follow-up. The men were stratified first by testosterone levels: group 1: total testosterone (TT) >12 nmol/L and free testosterone (FT) >0.25 nmol/L; Group 2: TT ≤12 nmol/L or FT ≤0.25 nmol/L. Group 2 was further stratified into those not on TRT (Group 2a) and those on TRT (Group 2b). Group 2b was further stratified by whether TRT was discontinued (Group 2b1) or not (Group 2b2). The principal outcome, mortality, was studied using Cox regression.
Introduction
Hypogonadism (HG), defined by low serum total testosterone (TT) concentrations (<12 nmol/L) and sexual symptoms, occurs in~70% men with type 2 diabetes (T2DM) [1] . Importantly, the European Male Ageing Study showed that erectile dysfunction and low TT independently predict allcause mortality [2] . Longitudinal studies by Muraleedaran et al. [3] and Hackett et al. [4] demonstrated that mortality in men with T2DM was significantly greater in those with TT ≤10.4 and ≤12.0 nmol/L, respectively. This increasing evidence has resulted in the American Association of Clinical Endocrinologists/American College of Endocrinology guidelines on obesity recommending that all men with T2DM and/or body mass index (BMI) >30 kg/m 2 should be screened for HG [5] .
The usefulness of testosterone replacement therapy (TRT) in reversing the risk of increased mortality has been assessed in longitudinal studies; Muraleedaran et al. [3] and Shores et al. [5] showed reduced mortality in men with low testosterone who underwent TRT, the former in men with T2DM. Our group also demonstrated that mortality was lower (ageadjusted hazard ratio [HR] 0.38, 95% CI 0.16-0.90) in 175 men with T2DM prescribed TRT than in 362 men with TT ≤12 nmol/L or free testosterone (FT) ≤0.25 nmol/L [4] . Further, the TRT-associated benefit appeared independent of statin and phosphodiesterase 5 (PDE5) inhibitor use. Importantly, PDE5 inhibitor use appeared to be strongly associated with lower mortality.
The impact of TRT on well-recognized markers of cardiovascular disease (CVD)-related mortality has been assessed in meta-analyses of randomized controlled trials (RCTs) lasting up to 12 months. TRT in men with and without T2DM, favourably affected total cholesterol (TC) levels, low-density lipoprotein cholesterol levels, weight, BMI, waist circumference, visceral fat mass, lean muscle mass, insulin levels, insulin resistance and high-sensitivity C-reactive protein levels. Neutral or minimal adverse effects have been observed with regard to high-density lipoprotein (HDL) cholesterol levels [2, [6] [7] [8] . Registry studies of men on TRT suggest that improvements in metabolic variables were maintained during a follow-up period of 8 years [9, 10] .
We now describe studies in 857 men with T2DM [4] , of whom 175 were initiated on TRT. Our aim was to further study the association between TRT and mortality by comparing mortality data in men (mean follow-up 3.8 years in the total cohort) whose TRT was discontinued with mortality data in men on continuous treatment. We then established whether factors associated with CVD and T2DM, such as BMI, glycated haemoglobin (HbA1c) levels, blood pressure (BP) and lipids (baseline and changes during followup) differed firstly, with testosterone status (TT >12 nmol/L and FT >0.25 nmol/L vs TT ≤12 nmol/L or FT ≤0.25 nmol/ L) and secondly, in men on TRT, compared with those untreated, and thirdly, in men stratified by whether their TRT was continuous or discontinued and fourthly, if they were associated with mortality. Finally, we determined whether the mortality associated with testosterone status and TRT varied amongst subgroups stratified by age, weight and BMI.
Methods

Patients and Treatment
Our cohort of 857 men with T2DM was screened for TT and FT between April 2007 and April 2009 from the patient registers of five English Midlands practices during recruitment for the BLAST RCT, a double-blind randomized placebo-controlled study designed to investigate the effects of long-acting testosterone undecanoate (1 000 mg) on sexual function scores and metabolic variables [11] . Using earlymorning TT and FT levels, the men were classified as having normal testosterone (Group 1: TT >12 nmol/L and FT >0.25 nmol/L, n = 320) or low testosterone (Group 2: TT ≤12 nmol/L or FT ≤0.25 nmol/L, n = 537). In men with a TT ≤12 nmol/L, a second morning measurement was taken in accordance with European Association of Urology guidelines [12] at least 2 weeks later. TRT (testosterone undecanoate) was initiated in 175 (Group 2b) of the 537 men in Group 2, and the remaining 362 men formed Group 2a. Subsequently, 32 of the men in Group 2b were converted to gel preparations, for reasons of personal or clinical preference. Group 2b comprised 78 men in whom treatment was continuous until the end of follow-up or death (Group 2b1) and 97 men in whom treatment was stopped (Group 2b2; Table 1 ). Details of the groups are shown in Fig. 1 
Laboratory Methods
Baseline biochemistry was assessed in fasting samples. All analyses were carried out in an accredited NHS Laboratory and subjected to daily internal and regular external quality assessment of accuracy and precision. TT was measured using the validated Roche common platform immunoassay. The reference range for adult males for this method was 7.3-28.1 nmol/L and the interassay coefficient of variation averaged 4.6%. FT was estimated using the equations of Vermeulen et al. [14] . Serum sex hormone-binding globulin, albumin and lipid levels were analysed using a Roche Modular automated analyzer (Roche Diagnostics, Burgess Hill, UK). HbA1c was measured in whole blood using a Tosoh G7 ion exchange high-performance liquid chromatography analyser (Tosoh Bioscience Ltd, Redditch, UK), the method was standardized using International Federation of Clinical Chemistry reference material ,and the results were adjusted to give derived National Glycohaemoglobin Standardization Programme units (%). Laboratory data from the total cohort were obtained from primary and secondary care databases. While testosterone 520 © 2018 The Authors BJU International © 2018 BJU International Table 1 Demographic and mortality data of the study group when classified by testosterone status and treatment. BMI, body mass index; BP, blood pressure; FT, free testosterone; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; PDE5, phosphodiesterase 5; TG, triglcyerides; TRT, testosterone replacement therapy; TT, total testosterone; SHBG, sex hormone-binding globulin. Data are mean (SD), unless otherwise indicated.
© 2018 The Authors BJU International © 2018 BJU International 521 levels were used to stratify the 857 men into three testosterone groups, as a consequence of technology updates in the primary care practices, testosterone data were subsequently unavailable in 24 men.
Statistics
Between-group differences in age and CVD risk factors were assessed with unpaired t-tests and chi-squared tests for discrete and continuous variables, respectively; initially between the men in Group 1 and Group 2 (untreated and treated combined), then between the men in Group 2a and Group 2b, and finally between the men in Group 2b1 and Group 2b2. Intra-category differences between initial and final visit were identified using paired t-tests. Cox regression models were used to compare survival data between the patient groups and CVD risk factors studied. STATA version 8 (College Station, TX, USA) was used for all the statistical analyses. Table 1 and Fig. 1 show the stratification of the 857 men with T2DM into Group 1 (320 men) and Group 2 (537 men). Group 2 was stratified into a Group 2a (362 men) and Group 2b (175 men) based on TRT. Group 2b was further stratified into 78 men who were on continuous TRT (Group 2b1, mean treatment duration 3.4 years) and 97 men whose treatment was discontinued (Group 2b2; TRT withdrawn after a mean of 12.7 months). Table 1 also shows baseline data on age, CVD risk factors and treatment details at the end of followup for each of the groups and subgroups.
Results
Description of Patient Groups
Comparison of Baseline Characteristics: Group 1 vs Group 2
At initial visit, the 320 men in Group 1 had significantly lower baseline BMI (P < 0.001), HbA1c (P = 0.033), systolic (P = 0.001) and diastolic (P = 0.042) BP, triglycerides (TG; P < 0.001) and higher HDL cholesterol (P < 0.001) than the 537 men in Group 2. There was no difference in smoking rates, with only 8% in both groups recorded as current smokers. No difference was detected between the two groups regarding age, TC or any of the treatments shown in Table 1 .
Comparison of Baseline Characteristics: Group 2 Subgroups
Men in Group 2b were younger (P < 0.001) and had higher baseline diastolic BP (P = 0.001), TG (P = 0.025) and TC (P < 0.001) values compared with men in Group 2a. More men in Group 2b had their diabetes diet controlled (P = 0.005) and fewer were on insulin (P = 0.002) compared with their Group 2a counterparts; however, no difference in HbA1c was noted between the two groups (P = 0.73). PDE5 inhibitor treatment was Of the 175 men in whom TRT was initiated, 78 were treated until final assessment (Group 2b1), whilst TRT was discontinued in 97 men (Group 2b2); interestingly, TRT was discontinued in older men (P < 0.001) with lower baseline diastolic BP (P = 0.005) and TC (P = 0.033). More men in Group 2b1 had their diabetes diet controlled (P < 0.001) and fewer men were on insulin (P = 0.019) compared with their Group 2b2 counterparts, but no difference in HbA1c was noted between the two groups (P = 0.25). Interestingly, statin treatment was lower (P = 0.010), but PDE5 inhibitor use higher (P < 0.001) in Group 2b1 men compared with those in Group 2b2. Table 2 shows baseline and changes in modifiable risk factors in each subgroup. Significant reductions in weight and BMI were observed in men who were not on TRT (Group 1 and Group 2a). No change in HbA1c was seen in any of the groups. Group 1 men showed significant, albeit clinically modest, changes in TC and HDL cholesterol, these changes were not apparent in any of the other groups. Interestingly, systolic BP fell in all groups, apart from Group 2b and Group 2b1, whilst diastolic BP decreased in all groups. Table 1 shows differences in mortality rates during follow-up in the subgroups: Group 1: 11.3% (mean follow-up 4.1 years, HR 0.59, 95% CI 0.39-0.89; P = 0.013); Group 2a: 16.85% (mean follow-up 3.6 years, reference group in the Cox regression); Group 2b1: 0% (mean follow-up 3.4 years, excluded from the Cox regression as no deaths occurred during follow-up); and Group 2b2: 6.19% (mean follow-up 4.0 years, mean duration of TRT 12.7 months, HR 0.46, 95% CI 0.17-1.07; P = 0.070). Thus, the highest mortality was observed in Group 2a. Within this group, baseline (TT either as a continuous variable or stratified by 8 and 10 nmol/L) was not significantly associated with mortality (Cox regression analyses adjusted for baseline age); TT (continuous variable, HR 0.99, 95% CI 0.91-1.08; P = 0.84, TT ≥8 nmol/L mortality rate 17.7%), HR 1.14, 95% CI 0.66-1.97, P = 0.65 (reference TT <8 nmol/L, mortality rate 16.5%), TT ≥10 nmol/L (mortality rate 17.3%), HR 1.18, 95% CI: 0.69-2.02, P = 0.54 (reference TT <10 nmol/L, mortality rate: 16.4%).
Changes in Modifiable Cardiovascular Disease Risk Factors at the End of Follow-up
Mortality in the Patient Groups
Use of PDE5 inhibitors was higher in Group 2b2 (23.7%) than in the reference Group 2a (14.6%). Hence, the analysis was repeated in men not on PDE5 inhibitors and a significant association with lower mortality was observed in Group 2b2 (HR 0.34, 95% CI 0.12-0.94; P = 0.037). Group 2b1 was not included in the analysis as there were no deaths during follow-up.
Next, we aimed to determine if each of the risk variables in Table 2 (baseline and change observed during follow-up) were related to mortality. In individual Cox regression analyses, weight, BMI, TC, TG, HDL cholesterol and BP (systolic and diastolic) were not associated with mortality, each model also including age and factorized testosterone status/TRT groups (Group 1, Group 2a [reference group] and Group 2b). Age was significantly associated with mortality in all the regression models. Compared with Group 2a (reference), Group 1 and Group 2b remained associated with lower mortality; statistical significance was observed in all the regression models apart from that including systolic BP. In that model, the association between Group 2b and mortality only approached statistical significance (HR 0.43, 95% CI 0.18-1.01; P = 0.053). Thus, the data from Table 2 and the Cox regression analyses suggest that the lower mortality associated with both Group 2b1 and Group 2b2 could not be accounted for by baseline weight, BMI, TC, TG, HDL cholesterol or BP, or by changes observed during the follow-up period.
Association between Testosterone Replacement Therapy and Mortality in Men Stratified by Age, Weight and Body Mass Index Table 3 shows the results of Cox regression analyses used to assess the association between testosterone status, TRT (reference: Group 2a) and mortality in men stratified by median values of age, weight and BMI. Age was included in all the analyses as the men in Group 2b were younger. In the first model, the total cohort of 857 men was stratified by median age (64.6 years). Age was associated with mortality only in men aged > 64.6 years. Further, the previously reported associations between mortality and testosterone status (Group 1 vs Group 2a) and TRT (Group 2b vs Group 2a) were also only evident in the older age group (Table 3) . This finding is illustrated (unadjusted for age) in Fig. 2 (Kaplan-Meier plot).
When the men were stratified by median baseline weight, age was associated with mortality in both groups; however, the reduced mortality associated with men in Group 1 and Group 2b (reference: Group 2a) was evident only in men who weighed ≤93.80 kg. A Kaplan-Meier plot (unadjusted for age) illustrates this in Fig. 3 . When median baseline BMI (30.6 kg/ m 2 ) was used to stratify the cohort, age was significantly associated with mortality in both groups. 
Discussion
Currently in the UK, men are prescribed TRT for the relief of bothersome symptoms and not for reduction of cardiovascular or all-cause mortality. Snyder et al. [15] , in the Testosterone trial, showed clear benefits in sexual function, mood, depression, quality of life, physical performance, vitality, anaemia and bone mineral density. Despite these positive outcomes, concern continues to exist regarding the cardiovascular safety of TRT, especially from the US Food and Drug Administration (FDA) (https://www.fda.gov/Drugs/DrugSafety/ucm436259.htmaccessed 18/07/2018), [16] but not in Europe [17] . In view of this, it is essential that the effects of TRT are extensively studied for outcomes and potential mechanism(s) leading to benefit. Table 1 as only patients with values documented at initial visit and final visit were included in the paired t-test analysis. We previously showed that low testosterone levels (Group 2a) were associated with increased mortality, and TRT (Group 2b) resulted in a significant reduction in mortality in men with T2DM [4, 18] . In the present study, using the same cohort of men, we investigated factors that influenced the above associations. Of the 175 men with low testosterone levels who initiated TRT, only 78 continued on the treatment at final review (Table 1) . TRT was withdrawn in the remaining 97 men, with the mean duration of treatment being 12.7 months.
No reason for discontinuation of treatment was available for the follow-on visits as these data were obtained from routine clinic visits and not an RCT, but discontinuation rates were very low (9/199) in the RCT and open extension studies [11] . Patients were treated with free medication within the RCT and extension study on the basis of screening levels and not clinical symptoms. As there was no requirement for GPs to provide ongoing medication under any National Institute for Health and Care Excellence (NICE) or primary care guidelines or targets, the onus was on the patient or clinician to justify continuation rather than seeking reasons for discontinuation. Baseline characteristics suggested that the decision not to continue prescribing at NHS expense was more likely in older men (mean age 61.8 years vs 54.0 years; P < 0.001). PDE5 inhibitor use was significantly higher in men continued on TRT (Group 2b1), which points to continued prescribing of TRT being linked with improvement in sexual function, and this was also shown in the RCT as being the major reason why patients chose to continue into the open-label extension phase. Long-term follow-up of men recruited for the BLAST RCT showed that the International Index of Erectile Function-Erectile Function score was significantly higher (P < 0.001) in men who continued on TRT (+8.6) compared with the men in whom TRT was discontinued (À2.6), this association was independent of PDE5 inhibitor use, suggesting that TRT was more likely to be continued in men experiencing benefits in sexual function [19] .
The mortality rate during follow-up was 0% in men continuing on TRT (Group 2b1) and 6.2% in men whose TRT was discontinued (Group 2b2); mortality in men with low testosterone not on TRT (Group 2a) was 16.9%. The lower mortality rate in Group 2b2 approached significance (P = 0.070) when compared with the reference Group 2a, and achieved statistical significance (P = 0.037) in men not on PDE5 inhibitors. Men on PDE5 inhibitors were excluded as we had previously found PDE5 inhibitor use to be strongly associated with lower mortality [4] . This hints that the benefits associated with TRT may extend well after discontinuation of TRT (mean duration of TRT 12.7 AE 9.1 months, mean total follow-up 4.0 AE 1.0 years). Metaanalyses of RCTs of TRT and all-cause mortality have been inconclusive because of small cohort size and insufficient duration (mean 32.5 weeks) [20] [21] [22] . Corona et al. [21] concluded that there was evidence of benefit with TRT from RCTs only in men with T2DM and metabolic syndrome. Long-term observational studies suggest possible benefit from TRT in terms of cardiovascular and all-cause mortality, especially with treatment duration of several years to achieve levels in the normal range [23] [24] [25] . Some observational studies excluded deaths and events within the first 6 months [21] , concluding that these were likely to be attributable to the previously under-treated HG. Despite this evidence, the previously mentioned 2013 FDA warning, based largely on two controversial publications [26, 27] , has not been updated. Observational studies, often based on healthcare registries, are considered subject to considerable bias because of heterogeneous populations, uncertain diagnosis, mixed delivery systems and poor information on compliance [28] . In men with HG and T2DM, TRT has been associated with improvement in HbA1c, TC, waist circumference and BMI in the BLAST RCT after 30 weeks when other concomitant medications were not altered [19, 29] . Long-term follow-up of these patients showed that only waist circumference reduction was maintained after a mean 3.8 years of routine care, perhaps as a result of treatment changes (diabetes, BP and dyslipidaemia) affecting weight and controlling HbA1c [19] . Our results in men screened for the BLAST RCT did not show improvement in HbA1c and BMI, probably for the same reason. Unfortunately, waist circumference was not routinely documented in this cohort. The Quality and Outcome Framework (QOF) in England, an incentive scheme and part of the general medical services contract for primary care in the UK sets annual targets for HbA1c and BP when treating patients with diabetes [30] . Treatment of dyslipidaemia is set out in the NICE clinical guidelines (CG 67; during the duration of this study, the TC target was to reduce TC by 25% or to < 4 mmol/L, whichever led to a lower TC level. CG 67 has been replaced by CG181, which advocates the use of CVD risk algorithms in patients with T2DM [31] . A study of HbA1c over 8 years following the issue of national diabetes guidelines [32] and the QOF showed convergence towards the HbA1c target of 7.5% [33] . Thus, we expect that the treatment of the men studied would have been titrated to achieve targets, as laid out in the QOF and national guidelines relating to individuals with T2DM. This was seen in both Groups 2b1 and 2b2 when no changes were observed in weight, BMI, HbA1c and lipids after a mean of 3.4 and 4.0 years' follow-up, respectively. In contrast, both weight and BMI (both not subject to national guidelines) decreased significantly in Groups 1 and 2a after a mean of 4.1 and 3.6 years' follow-up, respectively, but not in Group 2b. This cannot be explained by insulin treatment (which is associated with weight gain), which was lower in Group 2b. In Group 2b, in which an association with lower mortality was observed, only diastolic BP was lowered at the end of follow-up, a decrease also evident in the untreated men. Further, baseline levels and changes at the end of follow-up (HbA1c, lipids, weight, BMI and BP) were not associated with mortality. The association with lower mortality observed in Group 1 and Group 2b remained significant when the regression models were adjusted (baseline values and change) for lipids, HbA1c, weight, BMI and diastolic BP (Group 2b approached significance when adjusted for systolic BP, whilst Group 1 remained associated with lower mortality). This suggests that the increased mortality observed with lower testosterone levels and the reduction associated with TRT was independent of weight, BMI, glycaemic control, dyslipidaemia and BP.
In our opinion, many chronic pathologies are heterogeneous, with common phenotypes leading them to be grouped as single diseases [34] . We have previously shown that statins and fibrates exert greater effects in certain dyslipidaemic subgroups [35, 36] . With HG heterogeneity in mind, we wished to identify subgroups where the previously observed associations [4] were more marked. Age, weight and BMI were stratified by median values and the association between testosterone status/TRT and mortality was studied in each of the subgroups (Table 2 ). Baseline smoking rates, at 8% per group, were too low for stratification and this was also the case in the Testosterone trial [8, 15] . Subgroups stratified by HbA1c, lipids and BP were not used, as these would have been treated to target in primary care during follow-up. Interestingly, no significant association between testosterone status/TRT and mortality was observed in men aged ≤64.6 years. Even age, entered as a continuous variable, was not associated with mortality in these men. This could have been attributable to the low mortality rate of 4.2% in these men compared with 19.8% in complementary men aged >64.6 years. In men >64.6 years Group 1 and Group 2b showed significantly lower mortality compared to Group 2a, and age not surprisingly was also associated with mortality. We have previously shown that mortality rate in our cohort was in accordance with the exponential pattern described by Benjamin Gompertz, with greatest mortality reduction seen in older men with T2DM treated with statins, TRT and PDE5 inhibitors [18] . Although these data may suggest that TRT may be associated with less risk reduction in younger men, it must be remembered that our follow-up was relatively short. We need to be aware that, currently, TRT is not prescribed for risk reduction but for the relief of bothersome, often sexual, symptoms, that might be more relevant to younger men. Adopting lifestyle risk reduction as opposed to absolute and relative risk reduction will probably yield greater benefit and this would not preclude younger men from TRT [37] . The concept of lifetime risk reduction has been emphasized in the Joint British Societies 3 recommendations for prevention of CVD regarding lipid-lowering treatment [38] .
The effects of testosterone status/TRT on mortality were significant in men who weighed ≤93.8 kg as opposed to those who weighed >93.8 kg. In the BLAST RCT, TRT with testosterone undecanoate was associated with greater improvement in sexual symptoms in less obese men and those aged >60 years, perhaps as a result of lower serum levels of testosterone being achieved [39] . Our analysis suggests that improvement in mortality is also more marked in these men. Interestingly, obesity is associated with lower testosterone levels [40] . Suppression of the hypothalamic pituitary gonadal axis by adipokines and proinflammatory factors secreted by adiposities may be relevant [41] ; however, this does not explain our observation with regard to exogenous TRT, which is not subject to negative feedback. Our findings may be accounted for by the increased aromatase levels associated with male obesity, which may increase the conversion of testosterone to oestradiol and 526 © 2018 The Authors BJU International © 2018 BJU International potentially blunt the efficacy of TRT [42] . A prospective RCT with serial measurements of testosterone (TT and FT) and metabolites would be required to determine the mechanism(s) of the associations that we have presented.
The 857 patients studied comprised all the men with T2DM in five primary care practices; hence, no selection bias is expected. In view of the QOF, much of the required data was available as computerized records. Importantly, this included PDE5 inhibitor prescribing on the NHS, important as PDE5 inhibitors have been shown to be independently associated with lower mortality [4, 43, 44] . We were therefore able to carry out some analyses in men not on PDE5 inhibitors, thus eliminating its impact.
Limitations of the present study include the difference in age between some of the groups; younger men were more likely to be on TRT, especially uninterrupted TRT. This is perhaps attributable to the use of TRT being considered as treatment of sexual symptoms, which, in turn, may be perceived as more important in younger men. There was therefore a possible selection bias, with TRT reserved for younger and fitter men; however, the rate of erectile dysfunction, a predictor and independent risk factor for CVD and all-cause mortality [45] , was probably higher in Group 2b in view of higher use of PDE5 inhibitors in that group. We would have liked to investigate whether different testosterone delivery systems led to similar results but, unfortunately, there were insufficient data to study mortality in the 32 men who were switched to testosterone gels.
In conclusion, there are considerable variations in guidelines issued regarding testosterone measurement. The 2018 AUA guidelines recommend testosterone measurement in men with T2DM and/or erectile dysfunction, further stating that men with low testosterone levels should be informed of their increased cardiovascular risk [46] . By contrast, the 2018 Endocrine Society guidelines do not recommend either of these measures [47] . To achieve consensus it is essential that more information on outcomes, such as cardiovascular events and mortality, are obtained from RCTs and well-designed longitudinal studies. Furthermore, subgroups (e.g. stratification of the group by various TT/FT levels to refine TRT treatment thresholds) that obtain greater benefit must be identified.
The present study has many important findings that further our understanding of the benefits associated with TRT. The analyses carried out suggest that the reduction in mortality is not accounted for by improvements in CVD risk factors. In view of this, it is essential to carry out an RCT with mechanism (s) of benefit, as well as outcomes designed. The reduced mortality associated with TRT may last many years after discontinuation of treatment. We have shown that the greatest benefit in terms of reduction of all-cause mortality may be in older men, although we would not recommend restricting TRT to this group purely on the basis of lifetime risk reduction. Importantly, reduction in mortality was only seen in men weighing ≤93.8 kg. There is evidence that weight reduction could lead to higher testosterone levels and this has led some to argue that weight reduction should be at the expense of TRT. However, weight reduction without any other treatments has not been associated with symptomatic benefit in HG [48] . Men are prescribed and continue to take TRT for relieving of bothersome clinical symptoms, not for risk reduction. Our observations of reduced mortality in a relatively short period of time after TRT, together with data showing improvement in weight, BMI and waist circumference [9, 10] , suggest that concurrent weight-reducing measures and TRT in men with HG would yield even greater benefit.
